DDD does not offer a good investment opportunity due to challenging macroeconomic conditions and stiff competition.
The 3D printing specialist saw a double-digit fall in quarterly revenue. This was due largely to one client, however.
Stratasys reported declining sales and a big GAAP loss yesterday. Today, its rival in 3D printing, 3D Systems, reported pretty much the same thing.
3D Systems Corporation (NYSE:DDD ) Q2 2024 Earnings Conference Call August 29, 2024 5:00 PM ET Company Participants Mick McCloskey - Vice President, Investor Relations Jeffrey Graves - President & Chief Executive Officer Jeff Creech - Executive Vice President & Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Danny Eggerichs - Craig-Hallum Jim Ricchiuti - Needham & Company Ananda Baruah - Loop Capital Markets Operator Hello, and welcome to the 3D Systems First Half 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
3D Systems (DDD) first-quarter 2024 top-line growth suffers from challenging macroeconomic conditions.
3D Systems (DDD) and Precision Resource partner to transform additive manufacturing with advanced DMP technology, enhancing precision and performance in critical industries.
Many people overlook penny stocks due to the inherent risk of investing in them. The stocks are infamous for producing poor results and being too hard to trade profitably.
3D Systems (DDD) launches the EXT 800 Titan Pellet, transforming 3D printing with faster speeds and lower costs for diverse industrial applications.
Every forward-thinking investor is considering 3D printing stocks. The growing use of the technology in industries such as aerospace, automotive, healthcare and consumer items led to a $22 billion industry in 2023, estimated to expand 24% to $150 billion by 2032 from $28 billion in 2024.
3D Systems was one of the original big names in 3D printing technology but hasn't been able to profit from this yet. The company lost money in 2022 and again in 2023.
3D Systems (DDD) enhances digital dentistry, offering the broadest solutions portfolio, including clear aligners, night guards and advanced denture technology.
3D Systems is well-positioned to capitalize on the growing bioprinting industry, particularly in the field of 3D organ printing. The company's financials show significant challenges, including negative net income and high levels of debt, which may impact its ability to thrive in the short to medium term. Despite the potential in the organ printing market, I recommend holding off on investing in 3D Systems until its financial situation improves or it demonstrates strong growth in the next few years.